La presentazione è in caricamento. Aspetta per favore

La presentazione è in caricamento. Aspetta per favore

The Mediterranean School of Oncology 43 th course Highlights in the management of colorectal cancer Rome, 1-2 February 2007.

Copie: 1
The Mediterranean School of Oncology 45 th course Highlights in the management of ovarian cancer Rome, 5-6 October 2007.

Presentazioni simili


Presentazione sul tema: "The Mediterranean School of Oncology 43 th course Highlights in the management of colorectal cancer Rome, 1-2 February 2007."— Transcript della presentazione:

1 The Mediterranean School of Oncology 43 th course Highlights in the management of colorectal cancer Rome, 1-2 February 2007

2 Consorzio Interuniversitario Nazionale per la Bio-Oncologia The Mediterranean School of Oncology An educational program of:

3 Bologna Chieti-Pescara Ferrara Catanzaro Palermo Roma La Sapienza Napoli Federico II Perugia Ancona Teramo LAquila A Consortium among 14 Italian Universities Foggia Messina

4 CARCINOMA DEL COLON-RETTO SCENARIO GLOBALE 2a causa di morte per cancro nei paesi occidentali! ~1,000,000 nuovi casi ~ 500,000 decessi/anno Alla diagnosi: 70-80% malattia localizata, resecabile 50% stadio II 35% stadio III ~40% (~400,000/anno) ripresa di malattia dopo chirurgia potenzialmente curativa

5 5-FU Infusione continua LevamisoleLD leucovorin HD leucovorin Bolus Anni 90: ottimizzazione del 5-FU

6 Sopravvivenza mediana CRC metastatico, I a linea Best supportive care Median overall survival (months) ~4–6 months 12–14 months 5-FU/LV 19–20 months FOLFOX4 or CAPEOX ~15–16 months IFL or FOLFIRI 20.6 months FOLFOX6 FOLFIRI 18.3 months 5-FU/LV + bevacizumab 25.1 months IFL + BV OX 20.3 months IFL + bevacizumab

7 Nel 2007, cosa si può attendere un paziente affetto da carcinoma metastatico del colon-retto? Soparvvivenza globale: mesi Risposte oggettive:50-70% Tempo alla progressione:8-11+ mesi

8 Oltre la I linea I a linea FOLFOX + Bevacizumab III a linea Cetuximab +Irinotecan II a linea Irinotecan + 5-FU (Bevacizumab) V a linea FOLFOX + Cetuximab IV a linea Cetuximab + Bevacizumab+ Irinotecan VI a linea FOLFOX + Cetuximab + Bevacizumab VII a linea XX +YY ………….

9 Come identificare i pazienti R e NR alla terapia?

10 CRC – Criteri di selezione usuali 100 pazienti trattati con CT dopo 5 anni: 70 sono viventi anche senza CT (o-treated) 20 sono deceduti nonostante la CT Usando il profilo despressione genica Only 22.5% of pts will be overtreated

11 Patient goes to Familiy doctor/health centerPopulation-based screening Investigations & diagnostic testing Cancer diagnosedCancer not diagnosed Treatment Palliative care Continuing treatment Follow-upRelapseTerminal care Long-term survival Bereavement Cure

12 Two classes: 1. Foreign students (in English); 2. Italian residents All courses are accredited for CME by Ministero della Salute, Italy or/and ESMO

13 Courses/year Students/year By December 2006: 42 courses >2200 students

14 Scholarships Available to candidates <30 years of age. To apply for a scholarship: a brief curriculum vitae; a letter of presentation from an authorised officer at the institute of affiliation. For information: www. unich.it/mso.cinbo

15 MSO Course Calendar 1-2 February:Highlights in the management of colorectal cancer (E) February:Tumori del rene e melanoma: progressi della ricerca traslazionale e clinica March :Cardiotossicità da farmaci antitumorali: basi genetiche, diagnosi, prevenzione e terapia April :Highlights in the management of breast cancer (E) May :Presente e futuro della terapia del dolore neuropatico in oncologia 8-9 June :Personalized diagnostic and therapeutic strategies in oncology (E) July :Sessualità e cancro 5-6 October :I tumori dellovaio October :New oncology drugs pipeline update: from bench to bedside (E) November :Controversie in oncologia (E) Courses in English

16 Consorzio Interuniversitario Nazionale per la Bio-Oncologia A MSO/CINBOs pilot project The Formazione a Distanza in Oncologia (FADO) Program

17 FADO Program Teaching is made via satellite technology. Designed to build or enhance professional knowledge, skills, and leadership in oncology and related disciplines through distance/online education & training.

18 Target audience 1. Residents in medical oncology; 2. Ph.D. students (Dottorato di Ricerca) in oncology and related disciplines Consorzio Interuniversitario Nazionale per la Bio-Oncologia

19 FADO - Partners Technologies & services: Organization & management:

20 Consorzio Interuniversitario Nazionale per la Bio-Oncologia A MSO/CINBOs pilot project The Mediterranean Task Force for Cancer Control (MTCC)

21 courses in modular print format videoconferences; lectures-seminars-lessons; To provide a forum for distance learning discussion among CINBO member Universities and selected medical Institutions within the mediterranean area MTCC An innovative project to raise awareness about cancer prevention and early detection via satellite technology

22 Algeria Croatia EgyptFranceGreece Italy JordanLebanon LybiaMorocco Portugal SyriaSloveniaSpainTunisiaTurkey Palestine 1st Meeting of the Mediterranean Task Force for Cancer Prevention and Early Detection October 4 th, 2005 Taormina, Italy With the participation of delegates from: Albania


Scaricare ppt "The Mediterranean School of Oncology 43 th course Highlights in the management of colorectal cancer Rome, 1-2 February 2007."

Presentazioni simili


Annunci Google